New disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis are usually expensive and insurers, including Medicare, will often limit access. This study examined Medicare Advantage and ...

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR tr ...

BIRKERØD, DENMARK - ViroGates A/S ("ViroGates"), a medical technology company developing blood tests for measuring chronic inflammation ...

Oral brepocitinib 30 mg was superior to placebo for treating dermatomyositis in adults already receiving standard therapies, according to phase 3 data presented at the American Academy of Dermatology ...

Treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs failed to mitigate bone mineral density ...

Objective Although socioeconomic status has been linked to various rheumatoid arthritis (RA)-related outcomes, evidence on ...

For the first time, the U.S Securities and Exchange Commission has sought to clearly define different types of crypto assets and how the regulator will approach them, issuing those new standards ...

Medicare coverage of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) -- both under Medicare Advantage and in separate Part D plans -- is likely to leave many ...

People like typologies. They simplify complex subjects and make them easier to discuss. Sometimes, a typology will seem to be the standard. Look up “types of serial killers,” and you’ll likely get the ...

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...